Atypical retinocytoma with diffuse vitreous seeds: an insight

Retinocytoma is a rare benign form of retinoblastoma. It is usually found on routine examinations and also while screening families of patients with retinoblastoma. Distinctive features are a translucent retinal mass with calcification, retinal pigment epithelial disturbance, chorioretinal atrophy and absence of growth. We report a case with all the above features along with diffuse vitreous seeds and optical coherence tomographic documentation of intralesional cavitary lesions

Bevacizumab therapy for macular edema in central retinal vein occlusion: long-term results

There is no proven effective treatment for vision loss in central retinal vein occlusion [CRVO]. Bevacizumab has been reported in small series with limited follow-up, to have a positive effect in reducing cystoid macular edema [CME] and improving vision in CRVO. To report long-term results with the use of bevacizumab in CRVO. Prospective interventional case series included 15 patients, serially evaluated with best corrected visual acuity [BCVA], optical coherence tomography [OCT], fluorescein angiography, and tonometry. Results were statistically analyzed. Mean follow-up was 12 +/- 3.6 months [range, 6?18 months]; mean number of injections was 2.2 [range, 1?4] per patient. Statistically significant reduction of macular thickness [P < 0.001] was seen at six weeks [mean, 346 micro]; three months [mean, 353 micro]; six months [mean, 348 micro]; and final follow-up [mean, 342 micro]. Significant BCVA improvement was seen at six weeks [mean, 0.27 logMAR], three months [mean, 0.3 logMAR], three months [0.15 logMAR], and final follow-up [mean, 0.21 logMAR] [P = 0.009]. Also, 73.3% patients had BCVA improvement at the last follow-up. Intravitreal bevacizumab is an effective treatment option for CME in CRVO patients. Reinjections at appropriate timing, based on the OCT findings, are important for better visual outcome